Elsevier

Journal of Clinical Virology

Volume 71, October 2015, Pages 76-81
Journal of Clinical Virology

Comparison of the bioMérieux NucliSENS EasyQ HIV-1 v2.0–HIV-1 RNA quantification assay versus Abbott RealTime HIV-1 and Roche Cobas TaqMan HIV-1 v2.0 on current epidemic HIV-1 variants

https://doi.org/10.1016/j.jcv.2015.08.007Get rights and content

Highlights

  • We compared 3HIV-RNA viral load assays on samples representative of HIV-M subtypes.

  • We also evaluated their clinical specificity against HIV-non M divergent strains.

  • The 3 assays showed good overall correlation.

  • A wide dispersion in results was observed with the NucliSENS® EasyQ® HIV-1 v2.0.

Abstract

Background

An improved version of the bioMérieux NucliSENS® EasyQ® HIV-1 v2.0 has been introduced to overcome the underquantification observed with previous versions, especially with non-B HIV-1 subtypes.

Objectives

Comparing bioMérieux NucliSENS® EasyQ® HIV-1 v2.0 versus Roche Cobas CA/CTM v2.0 and Abbott RealTime HIV-1 assays for HIV-1 group M and non-M (N, O, P) viral load measurement.

Study design

The three assays were tested in parallel on 103HIV-1 group M plasma samples, and on non-group M HIV-1 culture supernatants.

Results

Values obtained for the 103HIV-1 group M plasma samples tested with bioMérieux assay showed good overall correlation compared to the 2 others. The Roche Cobas assay gave higher values than the bioMérieux assay, while Abbott and bioMérieux both displayed similar results. However, analysis showed a wider dispersion in results when comparing the bioMérieux NucliSENS® EasyQ® HIV-1 v2.0 and the other 2 techniques. All data taken into account, we observed frequent discrepancies in quantification, of the plasma samples and major differences above 1 log in 10/72 (13.8%). The quantification of non-M HIV groups in culture supernatant has shown variable results, with better quantification of HIV-O and of HIV-N respectively with the Abbott assay and the bioMérieux assay.

Conclusions

The bioMérieux NucliSENS® EasyQ® HIV-1 v2.0 showed improved sensitivity to non-B HIV-M subtypes compared to previous versions. Notwithstanding, we observed frequent discrepancies and a wide dispersion in results when comparing bioMérieux NucliSENS® EasyQ® HIV-1 v2.0 and the other 2 techniques.

Section snippets

Background

The choice of viral RNA quantification technique for determination of HIV-1 plasma viral load (pVL) is crucial and hence the main marker of antiretroviral treatment efficacy and a major endpoint in clinical trials. Automated techniques such as Abbott RealTime HIV-1 (Abbott RT HIV-1, Abbott Molecular, Rungis, France), Cobas® AmpliPrep/Cobas® TaqMan® HIV-1 v2.0 (CA/CTM v2.0, Roche Diagnostics, Meylan, France), and NucliSENS® EasyMAG®/NucliSENS® EasyQ® HIV-1 v2.0 (EM/EQ v2.0, bioMérieux) allow

Objectives

To evaluate the performance of the bioMérieux EM/EQ v2.0 assay, we compared its analytical and clinical sensitivity to that of Roche CA/CTM v2.0 and Abbott RT HIV-1 on samples representative of different HIV-M subtypes. As the diversity of HIV-1, in many African and European countries, is not limited to HIV-M, and since the bioMérieux is not recommended for the quantification of HIV-1 non-M strains, we also evaluated its clinical specificity against these divergent strains.

Study design

Frozen plasma (n = 103), from patients infected with HIV-M, were used to quantify the pVL with the 3 different assays. The freeze/thaw cycles on the split specimens were the same for each assay. These routine samples, sampled on EDTA anticoagulant, were previously centrifuged at 3000 × g for 20 min, decanted directly after centrifugation, and stored at –80 °C for batch testing. Registered leftover collection was used so that no additional blood samples were collected for this study. Subtypes were

Analysis of results below the quantification threshold

We first analyzed the false-negative results of each technique, compared to the other assay results (Table 1). A false negative result was defined as a result below the lower limit of quantification (LLQ) of the considered test, while at least one of the other tests quantified the viral load above this limit.

Overall, Roche gave the lowest rate of false negative results (0.97%; 1/103); it corresponded to a unique sample, only quantified with the bioMérieux kit at a low level of 54 copies/mL.

Discussion

We compared the performance of the NASBA® based bioMérieux V2.0 assay to the 2 more widely used techniques: the RT-PCR based Roche TaqMan® CA/CTM v2.0, and the Abbott RT HIV-1 assays. We used samples representative of a wide range of viral loads and of the current epidemic strains of HIV-1 [1]. Values obtained with the 3 different techniques showed good overall correlation.

First, we analyzed the occurrence of false negative results using the different techniques. As others have done [9], and

Funding

We are indebted to the Institut de Veille Sanitaire (InVS), the Agence National de Recherche contre le Sida et les hépatites virales (ANRS), and the Rouen University Hospital for financial support.

Competing interest

None declared.

Ethical approval

Not required.

Authors contribution

T.M., C.D., M.V., V.L., F.S., J.C.P. contributed to the conception and design of the work or analysis and interpretation of data. T.M., C.D., F.S., J.C.P. contributed to the drafting of the article. All authors have approved the manuscript to be submitted.

Acknowledgment

We thank the teams of the Virology Laboratories at Rouen University Hospital and St Louis University Hospital for their involvement in the study.

We are also grateful to Nikki Sabourin-Gibbs, Rouen University Hospital, for writing assistance and review of the manuscript in English.

References (22)

  • J.C. Plantier et al.

    Plasma RNA quantification and HIV-divergent strains

    J. Acquir. Immune Defic. Syndr.

    (2003)
  • Cited by (16)

    • Severe underquantification of HIV-1 group O isolates by major commercial PCR-based assays

      2020, Clinical Microbiology and Infection
      Citation Excerpt :

      Detection and precise quantification of HIV-1-O are especially important, considering the intrinsic presence of the C181Y and other natural polymorphisms in the reverse transcriptase gene that result in reduced susceptibility and resistance to some widely used antiretroviral drugs, notably the nonnucleoside reverse transcriptase inhibitors efavirenz and nevirapine [18,19]. Although older versions of common commercial nucleic acid test (NAT) assays, including the Roche CAP/CTM v1.0, were unable to detect HIV-1-O RNA and thus were restricted to exclusively analysing HIV-1-M strains, more recently available assays were designed to detect and quantify HIV-1-O, as stated by the manufacturer's package inserts and as suggested by previous scientific studies [5,16,20–22]. In this systematic study of 25 HIV-1-O isolates, we found that the performance of current diagnostic NAT tests, including the Abbott RealTime and Roche CAP/CTM v2.0 systems, remain problematic for detecting HIV-1-O.

    • Comparative performance of the Biocentric Generic Viral Load, Roche CAP/CTM v1.5, Roche CAP/CTM v2.0 and m2000 Abbott assays for quantifying HIV-1 B and non-B strains: Underestimation of some CRF02 strains

      2019, Journal of Clinical Virology
      Citation Excerpt :

      In laboratories receiving samples with high diverse subtype, performing a second technique in parallel may be necessary. Our results confirm that differences in performance between assays persist [19–22] and that current assays are not equivalent, as reported for the Nuclisens assay not adapted to subtype C [6,24]. It is obvious that no perfect technique exists, and it is challenging to overcome the difficulty of amplifying all HIV subtypes while genetic diversity continues to expand.

    • Identification of rare HIV-1 Group N, HBV AE, and HTLV-3 strains in rural South Cameroon

      2017, Virology
      Citation Excerpt :

      In summary, the rare HIV, HBV, and HTLV strains identified in the present study serve as evidence for the need to conduct surveillance, which is critical to the design of diagnostic assays that are able to accommodate viral diversity. Historically, viral diversity has challenged diagnostic assay performance, leading to under quantification or completely missed detection of divergent strains (Chevaliez et al., 2007; Kessler et al., 2013; Korn et al., 2009; LaRue et al., 2012; Mourez et al., 2015). By designing diagnostic assays to tolerate viral diversity, newly emerging strains can readily be detected without further modification to the assay, which was the case for the ARCHITECT HIV Ag/Ab Combo and RealTime HIV assays when the first Group P infection was initially identified (Plantier et al., 2009).

    • Field evaluation of an open and polyvalent universal HIV-1/SIVcpz/SIVgor quantitative RT-PCR assay for HIV-1 viral load monitoring in comparison to Abbott RealTime HIV-1 in Cameroon

      2016, Journal of Virological Methods
      Citation Excerpt :

      Results were compared with VL obtained with an FDA-approved assay, Abbott RealTime HIV-1. This assay is widely used and known to detect and quantify a wide diversity of HIV-1 group M and O strains (Mourez et al., 2015; Ndiaye et al., 2015; Tang et al., 2007). The study was conducted in Cameroon in the CREMER Virology Laboratory in Yaoundé, Cameroon, a national reference laboratory and accredited by WHO for HIV antiretroviral resistance surveillance.

    View all citing articles on Scopus
    1

    Equal contribution to the work.

    View full text